For fiscal year 2025 Q3, revenue was JPY 619.9 billion (YoY +3.1%), operating income was JPY 54.5 billion (YoY -1.7%), showing steady progress against full-year forecasts.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4523-20260209-04.pdf","jir_short_summary":"For fiscal year 2025 Q3, revenue was JPY 619.9 billion (YoY +3.1%), operating income was JPY 54.5 billion (YoY -1.7%), showing steady progress against full-year forecasts.","jir_summary":"### Performance Overview\nFor fiscal year 2025 Q3, revenue was JPY 619.9 billion (YoY +3.1%), driven by organic growth in the pharmaceutical business. Operating income was JPY 54.5 billion (YoY -1.7%) due to absence of one-off gains\/losses, but operating income contribution from the pharmaceutical segment expanded. Progress toward the full-year forecast is steady at 78.5% for revenue and 99.9% for operating income.\n\n### Business and Product Trends, and Pipeline\nPharmaceutical business revenue reached JPY 610.1 billion, up 7% YoY. Core products Lenvima (JPY 258.1 billion, +4% YoY), Dayvigo (JPY 47.7 billion, +18%), and Rekenvi (JPY 61.8 billion, +109%) showed strong growth. Investments were made for new product launches in Europe and Japan to strengthen the oncology pipeline. Initiatives to maximize product value are progressing, including SC-AI (subcutaneous injection form of Rekenvi) and diagnostic efficiency improvements using BBM.","jir_financial_highlights":"Revenue: JPY 619.9 billion (YoY +3.1%)\nOperating Income: JPY 54.5 billion (YoY -1.7%)\nNet Income Attributable to Owners of Parent: JPY 41.8 billion (YoY -8.1%)\nEPS (JPY): 148.31 (YoY -7.4%)\nPharmaceutical Business Revenue: JPY 610.1 billion (YoY +7.2%)\nFY2025 Full-Year Revenue Forecast: JPY 790.0 billion (Unknown)\nFY2025 Full-Year Operating Income Forecast: JPY 54.5 billion (Unknown)","jir_category":"","jir_hashtags":"#Eisai, #FinancialResultsBriefing, #JapaneseStocks","jir_key_figures":"Revenue: JPY 619.9 billion (YoY +3.1%)\nOperating Income: JPY 54.5 billion (YoY -1.7%)\nPharmaceutical Business Revenue: JPY 610.1 billion (YoY +7.2%)","jir_meta_title":"Eisai FY2025 Q3 Results: Revenue of JPY 619.9 Billion and Operating Income of JPY 54.5 Billion with Steady Progress Toward Full-Year Forecast","jir_meta_description":"Eisai reports FY2025 Q3 revenue of JPY 619.9 billion (YoY +3.1%) and operating income of JPY 54.5 billion (YoY -1.7%). Strong pharmaceutical business drives steady progress toward full-year targets.","jir_og_title":"Eisai Announces FY2025 Q3 Financial Results","jir_og_description":"With revenue of JPY 619.9 billion and operating income of JPY 54.5 billion, Eisai's pharmaceutical business shows growth and steady progress against full-year forecasts.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (JPY Billions)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024 Apr-Dec\\\",\\\"FY2025 Apr-Dec\\\",\\\"FY2025 Full-Year Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[6012,6199,7900],\\\"backgroundColor\\\":\\\"#007bff\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (JPY Billions)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024 Apr-Dec\\\",\\\"FY2025 Apr-Dec\\\",\\\"FY2025 Full-Year Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[554,545,545],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Pharmaceutical Business Revenue (JPY Billions)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024 Apr-Dec\\\",\\\"FY2025 Apr-Dec\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Pharmaceutical Business Revenue\\\",\\\"data\\\":[5691,6101],\\\"backgroundColor\\\":\\\"#17a2b8\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"product_revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Core Product Revenue (JPY Billions)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Lenvima\\\",\\\"Dayvigo\\\",\\\"Rekenvi\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2025 Apr-Dec Results\\\",\\\"data\\\":[2581,477,618],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"region_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Lenvima Revenue by Region (JPY Billions)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Americas\\\",\\\"Japan\\\",\\\"China\\\",\\\"EMEA\\\",\\\"East Asia & Global South\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2024 Apr-Dec\\\",\\\"data\\\":[1755,106,192,314,114],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"FY2025 Apr-Dec\\\",\\\"data\\\":[1786,107,193,363,132],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26044","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n